MONTPELLIER, France, Oct. 1, 2015 (GLOBE NEWSWIRE) -- MEDTECH (Euronext, FR0010892950 – ROSA), a company specialized in designing, developing and marketing innovative surgical assistance robots, is pleased to announce the direct sale of three of its ROSA robots during the fiscal first quarter 2016 (quarterly period ended September 30, 2015).
One ROSA sale was by agreement with Frankfurt University Hospital, one of the largest health establishments in Germany with more than 3,000 patients receiving treatment for neurological disorders. The internationally famous neurosurgery department offers new approaches for the treatment of brain and spine diseases in its special care unit equipped with the latest technology.
Lucile Packard Children's Hospital, Stanford (California), a reference center for pediatrics, especially for the treatment of epilepsy, also recently installed a ROSA robot. This establishment was rated by U.S. News & World Report as one of the 10 best children's hospitals in the United States for the quality of its healthcare.
The third acquisition was by Rady Children's Hospital, San Diego (California). The hospital is a pediatric establishment that has been honored for the excellence of its neurology and neurosurgery care. It was recently classified among the 50 best children's hospitals in the United States by U.S. News & World Report for the fifth consecutive year.
Bertin Nahum, CEO and Founder of Medtech commented: "We are delighted by the expansion of our business in the European and North American markets. These three sales to renowned establishments give us a strong start to the fiscal year, confirming the rapid expansion of Medtech's commercial activity and the strong interest in ROSA technology for these growing markets."
Next communication: Q1 results for Financial Year 2015/2016 (ended September 30, 2015) on October 6, before the stock market opens.
Founded in 2002 by Bertin NAHUM and based near Montpellier, MEDTECH is a European specialist in the design, development and marketing of innovative robotic appliances to assist surgeons during their medico-surgical interventions, thus contributing to the implementation of safer, more efficient, less-invasive treatment.
In 2007, MEDTECH developed ROSA™, an innovative technological device devoted to brain surgery procedures. ROSA™ has been approved in Europe, the United States and Canada.
In 2013, MEDTECH received the "European Company of the Year Award" in the "robotic neurosurgery" category from Frost & Sullivan.
In July 2014, MEDTECH obtained the CE marking for its new product ROSA™ Spine, a robotic- assistive device for minimally invasive surgery of the spine.
In October 2014, MEDTECH won the "Révélation" prize in the Mediterranean Deloitte Technology Fast 50 Awards.
CONTACT: CONTACT MEDTECH Christophe Sibillin Chief Financial Officer Tel: +33 (0)4 67 10 77 40 INVESTORS Corinne Puissant Tel: +33 (0)1 53 67 36 77 email@example.com PRESS Alexandra Prisa (EU) Tel.: +33(0)1 53 67 36 90 firstname.lastname@example.org Joanna Zimmerman (US) Tel: +1 646-536-7006 email@example.com